Based on results of a study published earlier this week in The BMJ, angiotensin-converting-enzyme (ACE) inhibitors were associated with an increased risk of lung cancer, compared with a similar, but distinct type of blood pressure medication known as angiotensin-receptor blockers (ARBs).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,